FMC Corporation enters the final days of Q2 with its most aggressive short positioning in years — and the borrow market tightening at a pace that makes the setup genuinely interesting ahead of late-July earnings.
The short interest story is the week's headline. Bears have piled in hard: short interest climbed nearly 20% in a single week to reach 16.9% of the free float, up from roughly 10.3% at the end of May — a 63% increase in one month. That puts roughly 21 million shares short, against a stock trading at $11.50. The conviction behind this build is notable given the scale and speed of the move.
What's equally striking is what has happened in the borrow market alongside that buildup. Availability has collapsed — from over 1,000% a month ago, when shares were easy to find, down to just 157% today, with the most dramatic tightening coming in the past two sessions alone (it was still at 777% on June 26). Borrow is still technically available, but the direction of travel is unmistakable: the pool is shrinking fast as new shorts compete for the same inventory. The cost to borrow has more than doubled over the week to 0.88%, still low in absolute terms but a meaningful directional signal when paired with collapsing availability. The ORTEX short score jumped to 71 on June 30 from 57 just eleven days earlier — its highest reading in the tracked window, and one that ranks in the bottom 3rd percentile of all stocks by short score.
Options traders are not reading the setup the same way. The put/call ratio is running near its 52-week low at 0.33, well below its 20-day average of 0.36, and more than a standard deviation below that average — suggesting call interest is actually elevated relative to recent norms. That's a divergence worth naming: short sellers are betting heavily on continued downside while options flow leans the other way. Either the short book is hedged via calls, or there are two distinct investor groups with opposite views.
The Street sits firmly on the sidelines. Every analyst on record carries a Hold-equivalent rating — Neutral, Sector Perform, Equal-Weight — except Goldman Sachs, which maintained its Buy with a $21 target in April, and Mizuho at Outperform with a $20 target. The consensus mean target is $16.63, nearly 45% above the current price. Citigroup moved most recently, trimming its target from $17 to $14 on June 22 while staying Neutral. The bear case is well-understood: a 9% year-over-year price decline in Q1 driven by Brazilian competition, below-consensus Q2 guidance, and persistent channel destocking that has taken longer to clear than expected. Bulls point to management's confidence in roughly $600 million of implied H2 EBITDA, driven by Latin America seasonal volume recovery and improving U.S. momentum in Q2. Valuation is cheap — the P/E has compressed to 5.8x over the past month, and the price-to-book sits at just 0.69x — but cheap multiples have not been enough to attract buyers. The EPS surprise factor score ranks in the 97th percentile, a signal that when FMC does beat, it tends to beat meaningfully.
The CEO, Pierre Brondeau, sold 34,177 shares at $10.80 on June 11 — a transaction worth roughly $369,000. The significance score on that trade is low, and it came after a string of small routine director sales in late April around $15.56. The net insider position over the past 90 days is modestly positive in share terms, reflecting a director purchase of roughly 18,000 shares in March at $13.83. The net picture is mixed rather than alarming, but the CEO selling near multi-year lows is a detail worth noting.
Among peers, CTVA gained 7% on the week while FMC rose 4.4% — but FMC is still down 16% over the past month against CTVA's steadier footing. SQM and OLN both lost ground on the week, down 3.2% and 7.6% respectively, suggesting the chemicals group is not uniformly weak. FMC's underperformance looks stock-specific rather than sector-driven.
With Q2 results due July 29, the next few weeks will test whether the H2 recovery management has guided toward begins to show in the numbers — and whether a borrow market that has tightened from 1,000% availability to 157% in thirty days has further to run before something has to give.
See the live data behind this article on ORTEX.
Open FMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
